We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Combined Use of Assays Identifies Cancer Patient Response to Crizotinib

By LabMedica International staff writers
Posted on 19 Sep 2016
Print article
Image: A positive case of lung tissue detected by IHC-staining for anaplastic lymphoma kinase (ALK) with Ventana ALK (D5F3) CDx assay (Photo courtesy of Ventana).
Image: A positive case of lung tissue detected by IHC-staining for anaplastic lymphoma kinase (ALK) with Ventana ALK (D5F3) CDx assay (Photo courtesy of Ventana).
In screening of a large cohort for anaplastic lymphoma kinase (ALK) fusions through both fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) assays, researchers found many non-small cell lung cancer (NSCLC) patients who had negative and atypical FISH patterns accompanied with positive IHC results, who showed response to crizotinib treatment.

ALK gene rearrangements are found in 3-5% of patients with NSCLC. Identification of appropriate patient population with reliable detective methods is the key to use of targeted therapies. It is routine clinical practice to screen patients with adenocarcinoma NSCLC for ALK rearrangements due to the availability of ALK inhibitors and for their ability to provide remarkable benefit to patients. FISH has long been the gold standard used to screen patients for ALK rearrangements. However, IHC platforms that are used to detect overexpression of protein caused by ALK gene rearrangements have been found to be both highly sensitive and specific in determining ALK status in patients. Further, several studies have shown that patients with tumors that were ALK negative (ALK-) via FISH were ALK positive (ALK+) via IHC, and that those ALK+ patients showed response when treated with the ALK inhibitor crizotinib.

The discordant FISH and IHC phenomenon showed the need for further examination to identify the existence of unknown ALK fusion genes and led to the new study led by investigators at Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China). Of the 3,128 cases screened, 2,991 cases were subjected to both FISH and IHC analysis. IHC was performed with the FDA-approved Ventana-D5F3 IHC assay. 14 cases with negative and atypical FISH demonstrated IHC positivity (11 cases were ALK- via FISH and ALK+ via IHC; 3 cases were atypical FISH patterns and ALK+ via IHC). These 14 cases were further investigated using targeted next-generation sequencing (NGS), which revealed that 8 cases housed EML4-ALKfusions, 2 cases revealed novel ALK fusion partners (BIRC6 and PICALM), 1 case had a novel translocation partner (CEBPζ), and 3 patients did not exhibit any type of ALK fusions. Among all 14 patients, 4 patients received crizotinib treatment and demonstrated partial responses at the end of follow-up.

The authors commented that, “The most valuable finding of our study was that patients with EML4-ALK fusion or other novel complicated rearrangements could test negative via FISH and positive via IHC and these patients could possibly benefit from ALK-targeted therapy. Based on these findings, combinational assay of FISH and IHC methods are highly recommended in routine pathological diagnosis and when negative and atypical FISH patterns are accompanied by positivity in IHC.”

The study, by Li W, Zhang J, et al, was published September 7, 2016, online ahead of print in the Journal of Thoracic Oncology.

Related Links:
Chinese Academy of Medical Sciences and Peking Union Medical College

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.